Zaloguj Zarejestruj się zadarmo

Acelrx Pharmaceuticals Inc organizacji SMA 50

Jaka jest wartość SMA 50 organizacji Acelrx Pharmaceuticals Inc?

Wartość SMA 50 organizacji Acelrx Pharmaceuticals Inc to $1 -29.07%

Jaka jest definicja SMA 50?



SMA 50 to średnia cena akcji z ostatnich 50 dni, obliczona jako nieważona średnia z ostatnich 50 cen zamknięcia akcji.

Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.

Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.

SMA 50 firm w Health Care sektor na NASDAQ w porównaniu do Acelrx Pharmaceuticals Inc

Czym się zajmuję organizacja Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Firmy z sma 50 podobne do Acelrx Pharmaceuticals Inc